CLDX (Celldex Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

CLDX (Celldex Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

Mkt Cap$2B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$2M

Net Income (TTM)-$259M

EPS (TTM)-$3.90

Free Cash Flow (TTM)-$213M

Gross Margin100.0%

Op. Margin-19160.0%

Net Margin-17253.3%

FCF Margin-14224.7%

P/S Ratio (TTM)1405.2x

P/E Ratio (TTM)—

YoY Rev Growth-78.6%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$967K	-$26M	-$32M
Q2 23	$268K	-$26M	-$33M
Q3 23	$2M	$750K	-$41M
Q4 23	$4M	-$26M	-$48M
Q1 24	$156K	-$619K	-$41M
Q2 24	$2M	$2M	-$46M
Q3 24	$3M	$3M	-$52M
Q4 24	$1M	$356K	-$56M
Q1 25	$695K	$695K	-$63M
Q2 25	$730K	$730K	-$64M
Q3 25	$0	$0	-$74M
Q4 25	$75K	$75K	-$87M

Valuation

Quarter	P/S	P/E
Q1 23	669.1x	—
Q2 23	647.6x	—
Q3 23	482.9x	—
Q4 23	306.2x	—
Q1 24	347.1x	—
Q2 24	253.9x	—
Q3 24	211.3x	—
Q4 24	300.3x	—
Q1 25	278.8x	—
Q2 25	364.0x	—
Q3 25	810.7x	—
Q4 25	1405.2x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$29M	-$29M
Q2 23	-$27M	-$28M
Q3 23	-$19M	-$19M
Q4 23	-$33M	-$33M
Q1 24	-$41M	-$41M
Q2 24	-$29M	-$30M
Q3 24	-$55M	-$55M
Q4 24	-$32M	-$33M
Q1 25	-$54M	-$55M
Q2 25	-$44M	-$45M
Q3 25	-$49M	-$49M
Q4 25	-$64M	-$65M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$585K
Q2 23	$410K
Q3 23	$157K
Q4 23	$666K
Q1 24	$344K
Q2 24	$274K
Q3 24	$618K
Q4 24	$756K
Q1 25	$265K
Q2 25	$728K
Q3 25	$440K
Q4 25	$993K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+455.7%	+42.7%
Q2 23	+64.4%	-8.4%
Q3 23	+272.7%	+52.1%
Q4 23	+156.1%	+75.5%
Q1 24	-83.9%	+21.9%
Q2 24	+832.1%	+45.8%
Q3 24	+110.3%	+29.4%
Q4 24	-71.6%	+10.5%
Q1 25	+345.5%	+55.6%
Q2 25	-70.8%	+32.3%
Q3 25	-100.0%	+33.1%
Q4 25	-93.6%	+52.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$4M	448.8%
Q2 23	$5M	1946.6%
Q3 23	$7M	469.4%
Q4 23	$7M	174.6%
Q1 24	$7M	4616.7%
Q2 24	$8M	305.8%
Q3 24	$10M	301.5%
Q4 24	$10M	832.3%
Q1 25	$9M	1340.4%
Q2 25	$9M	1259.0%
Q3 25	$9M	—
Q4 25	$9M	11878.7%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$27M	$7M
Q2 23	$26M	$7M
Q3 23	$35M	$8M
Q4 23	$30M	$9M
Q1 24	$31M	$9M
Q2 24	$39M	$9M
Q3 24	$3K	$10M
Q4 24	$46M	$10M
Q1 25	$53M	$11M
Q2 25	$54M	$10M
Q3 25	$63M	$11M
Q4 25	$75M	$12M

Revenue Segments

Quarter	Grant	Service
Q1 23	$967K	—
Q2 23	$252K	$16K
Q3 23	$2M	$2K
Q1 24	$154K	$2K
Q2 24	$2M	$2K
Q3 24	$3M	$3K
Q1 25	$645K	$50K
Q2 25	$723K	$7K
Q3 25	$1M	$57K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$54M	$224M	$278M
Q2 23	$28M	$224M	$253M
Q3 23	$21M	$214M	$235M
Q4 23	$35M	$387M	$422M
Q1 24	$115M	$709M	$824M
Q2 24	$43M	$760M	$802M
Q3 24	$36M	$720M	$756M
Q4 24	$28M	$697M	$725M
Q1 25	$17M	$656M	$673M
Q2 25	$23M	$607M	$630M
Q3 25	$36M	$547M	$583M
Q4 25	$29M	$490M	$519M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	47M	+0.2%
Q2 23	47M	+0.1%
Q3 23	47M	+0.0%
Q4 23	52M	+10.1%
Q1 24	59M	+13.2%
Q2 24	66M	+12.1%
Q3 24	66M	+0.4%
Q4 24	66M	+0.1%
Q1 25	66M	+0.0%
Q2 25	66M	+0.0%
Q3 25	66M	+0.0%
Q4 25	67M	+0.1%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$22K	161
FY 15	$28K	199
FY 16	$32K	210
FY 17	$65K	197
FY 18	$70K	137
FY 19	$27K	130
FY 20	$59K	125
FY 21	$35K	134
FY 22	$16K	148
FY 23	$43K	160
FY 24	$38K	186
FY 25	$8	200K